The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Abstract
PURPOSE: To determine the relative efficacy of an intensive cyclophosphamide, epirubicin, and fluorouracil (CEF) adjuvant chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive breast cancer. PATIENTS AND METHODS: Premenopausal women with node-positive breast cancer were randomly allocated to receive either cyclophosphamide 100 mg/m2 orally days 1 through 14; methotrexate 40 mg/m2 intravenously (i.v.) days 1 and 8; and fluorouracil 600 mg/m2 i.v. days 1 and 8 or cyclophosphomide 75 mg/m2 orally days 1 through 14; epirubicin 60 mg/m2 i.v. days 1 and 8; and fluorouracil 500 mg/m2 i.v. days 1 and 8. Each cycle was administered monthly for 6 months. Patients administered CEF received antibiotic prophylaxis with cotrimoxazole two tablets twice a day for the duration of chemotherapy. RESULTS: The median follow-up was 59 months. One hundred sixty-nine of the 359 CMF patients developed recurrence compared with 132 of the 351 CEF patients. The corresponding 5-year relapse-free survival rates were 53% and 63%, respectively (P = .009). One hundred seven CMF patients died compared with 85 CEF patients. The corresponding 5-year actuarial survival rates were 70% and 77%, respectively (P = .03). The rate of hospitalization for febrile neutropenia was 1.1% in the CMF group compared with 8.5% in the CEF group. There was one case of congestive heart failure in a patient who received CMF compared with none in the CEF group. Acute leukemia occurred in five patients in the CEF group. CONCLUSION: The results of this trial show the superiority of CEF over CMF in terms of both disease-free and overall survival in premenopausal women with axillary node-positive breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Applied Regression Analysis and Other Multivariable Methods
Walker, E. (1989) · Technometrics · doi:10.1080/00401706.1989.10488486 · Cited by 8,538
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., De Lena, M., Tancini, G., Bajetta, E., Musumeci, R., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602192940801 · Cited by 1,329
Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Self-citationAnalysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
Hryniuk, W., & Levine, M. N. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1162 · Cited by 456
Self-citationBonadonna, G. (1995) · JAMA · doi:10.1001/jama.273.7.542 · Cited by 352
Jain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., Currie, V, Schwartz, W., Cassidy, C., Petroni, G. R., & Young, C. W. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.818 · Cited by 251
Plosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199345050-00011 · Cited by 223
Quality of life in stage II breast cancer: an instrument for clinical trials.
Levine, M. N., Guyatt, G. H., Gent, M., De Pauw, S., Goodyear, M. D., Hryniuk, W. M., Arnold, A., Findlay, B., Skillings, J. R., & Bramwell, V. H. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1798 · Cited by 223
Self-citationCardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
Torti, F. M., Bristow, M. R., Lum, B. L., Carter, S. K., Howes, A. E., Aston, D. A., Brown, B. W., Hannigan, J. F., Meyers, F. J., & Mitchell, E. P. (1986) · PubMed · Cited by 197
(1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.976 · Cited by 167
Drugs ten years later: Epirubicin
Bonadonna, G., Gianni, L., Santoro, A., Bonfante, V., Bidoli, P., Casali, P. G., Demicheli, R., & Valagussa, P. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058514 · Cited by 154
Meyer, R. M., Browman, G. P., Samosh, M., Benger, A. M., Bryant‐Lukosius, D., Wilson, W. E., Frank, G. L., Leber, B. F., Sternbach, M. S., & Foster, G. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2386 · Cited by 141
Coukell, A. J., & Faulds, D. M. (1997) · Drugs · doi:10.2165/00003495-199753030-00008 · Cited by 116
Assessing the Reliability of Two Toxicity Scales: Implications for Interpreting Toxicity Data
Brundage, M., Pater, J. L., & Zee, B. C.-Y. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.14.1138 · Cited by 115
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
Nielsen, D. L., Jensen, J. B., Dombernowsky, P., Munck, O., Fogh, J., Brynjolf, I., Havsteen, H., & Hansen, M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1806 · Cited by 99
Levine, M. N., Bramwell, V. H. C., Pritchard, K. I., Perrault, D. J., Findlay, B., Abu-Zahra, H., Warr, D. G., Arnold, A., & Skillings, J. R. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90573-x · Cited by 24
Self-citation
Cited by
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., Bekele, B. N., Raber-Durlacher, J., Donnelly, J. P., Rubenstein, E. B., et al. (2004) · Cancer · doi:10.1002/cncr.20162 · Cited by 1,417
Aapro, M. S., Bohlius, J., Cameron, D. A., Lago, L. D., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.013 · Cited by 1,090
Metadata
- Authors
- Levine, M. N., Bramwell, V. H., Pritchard, K. I., Norris, B. D., Shepherd, L. E., Abu-Zahra, H., Findlay, B., Warr, D., Bowman, D., Myles, J., Arnold, A., Vandenberg, T., MacKenzie, R., Robert, J., Ottaway, J., Burnell, M., Williams, C. K., & Tu, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-08
- Volume
- 16
- Issue
- 8
- Pages
- 2651-2658
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1848579801
- Cited by
- 617
- References
- 20
- FWCI
- 14.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.